Kyverna reports 49% median walking improvement in stiff-person syndrome trial
AI Summary- Kyverna reported 12-month miv-cel results from stiff-person syndrome and generalized myasthenia gravis trials.
- 49% median walking improvement was recorded among 26 stiff-person syndrome patients at month 12.
- Kyverna plans to complete rolling Biologics License Application submission in fourth-quarter 2026.